news
Main COVID-19 protease revealed, enabling screening of potential drugs
Chinese researchers who determined the crystal structure of the COVID-19 protease Mpro used this information to screen over 10,000 compounds to combat the coronavirus.
List view / Grid view
Proteomics
news
Human lung epithelium model being tested as a platform for COVID-19 research
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
news
Scientists identify fusion peptide as promising COVID-19 drug target
Researchers working on related coronaviruses SARS and MERS have identified the membrane fusion peptide on the Spike protein as a possible drug target for SARS-CoV-2, the virus causing COVID-19.
video
Video: Increased reproducibility with KingFisher™ instruments
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
news
Researchers reveal how SARS antibody binds to COVID-19 coronavirus
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
news
Novel tuberculosis transport protein could be target of new treatments
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news
TAp63, miRNAs and AURKA: novel cutaneous squamous cell carcinoma drug targets
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
news
Researchers optimise PROTAC technology to dispose of cancer proteins
Researchers have optimised PROTAC substances to degrade and dispose of proteins that support cancers, by customising their structure and selecting the best ligases.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
news
Imaging technique allows study of early stage Alzheimer’s disease
Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.
news
Map of COVID-19 and human protein interactions reveals drug targets
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
article
Targeted protein degradation: the next wave of therapeutics
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
news
Preliminary SARS-CoV-2 protease inhibitor shows efficacy in mice
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
